Organon & Co. (NYSE:OGN) Receives Average Rating of “Reduce” from Brokerages

Organon & Co. (NYSE:OGN) has earned a consensus rating of “Reduce” from the seven brokerages that are presently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating and five have issued a hold rating on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $11.40.

A number of brokerages have recently commented on OGN. Weiss Ratings raised Organon & Co. from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, May 15th. BNP Paribas Exane reissued a “neutral” rating and set a $14.00 price objective (up from $12.00) on shares of Organon & Co. in a report on Wednesday, April 29th. Barclays increased their price objective on Organon & Co. from $7.50 to $8.00 and gave the company an “underweight” rating in a report on Tuesday, February 24th. Zacks Research raised Organon & Co. from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 14th. Finally, Piper Sandler raised Organon & Co. from an “underweight” rating to a “neutral” rating and increased their price objective for the company from $5.00 to $14.00 in a report on Tuesday, April 28th.

Insiders Place Their Bets

In other Organon & Co. news, SVP Lynette Holzbaur bought 26,448 shares of the firm’s stock in a transaction that occurred on Wednesday, May 6th. The stock was purchased at an average price of $13.35 per share, for a total transaction of $353,080.80. Following the purchase, the senior vice president directly owned 52,851 shares in the company, valued at $705,560.85. This trade represents a 100.17% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 1.62% of the stock is currently owned by insiders.

Institutional Trading of Organon & Co.

Several hedge funds have recently added to or reduced their stakes in the business. Cetera Investment Advisers boosted its stake in Organon & Co. by 1.7% during the 1st quarter. Cetera Investment Advisers now owns 48,073 shares of the company’s stock valued at $288,000 after purchasing an additional 788 shares during the period. State of Alaska Department of Revenue boosted its stake in Organon & Co. by 0.6% during the 4th quarter. State of Alaska Department of Revenue now owns 278,379 shares of the company’s stock valued at $1,995,000 after purchasing an additional 1,570 shares during the period. Integrated Wealth Concepts LLC boosted its stake in Organon & Co. by 2.8% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 58,648 shares of the company’s stock valued at $626,000 after purchasing an additional 1,594 shares during the period. Rothschild Investment LLC boosted its stake in Organon & Co. by 73.1% during the 3rd quarter. Rothschild Investment LLC now owns 3,899 shares of the company’s stock valued at $42,000 after purchasing an additional 1,646 shares during the period. Finally, Rafferty Asset Management LLC boosted its stake in Organon & Co. by 8.5% during the 2nd quarter. Rafferty Asset Management LLC now owns 23,578 shares of the company’s stock valued at $228,000 after purchasing an additional 1,847 shares during the period. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Stock Performance

Shares of NYSE OGN opened at $13.43 on Wednesday. The company has a debt-to-equity ratio of 9.47, a quick ratio of 1.42 and a current ratio of 1.97. The firm has a market cap of $3.53 billion, a price-to-earnings ratio of 14.44, a P/E/G ratio of 1.24 and a beta of 1.55. The business’s 50-day simple moving average is $11.90 and its 200-day simple moving average is $8.98. Organon & Co. has a 52 week low of $5.69 and a 52 week high of $13.49.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings data on Thursday, April 30th. The company reported $0.71 EPS for the quarter, missing analysts’ consensus estimates of $0.83 by ($0.12). The company had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.49 billion. Organon & Co. had a net margin of 3.99% and a return on equity of 99.95%. The business’s revenue was down 3.5% on a year-over-year basis. During the same period in the prior year, the company posted $1.02 EPS. As a group, equities research analysts expect that Organon & Co. will post 3.23 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 11th. Investors of record on Monday, May 11th were paid a dividend of $0.02 per share. The ex-dividend date was Monday, May 11th. This represents a $0.08 annualized dividend and a yield of 0.6%. Organon & Co.’s dividend payout ratio is presently 8.60%.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.